

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 9/06, C12Q 1/26	A1	(11) International Publication Number: WO 90/10061 (43) International Publication Date: 7 September 1990 (07.09.90)
(21) International Application Number: PCT/AU90/00085 (22) International Filing Date: 2 March 1990 (02.03.90) (30) Priority data: PJ 3017 2 March 1989 (02.03.89) AU (71) Applicant (for all designated States except US): GRIFFITH UNIVERSITY [AU/AU]; Kessels Road, Nathan, QLD 4111 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only) : COWLEY, David, Michael [AU/AU]; 18 Amarna Street, Eight Mile Plains, QLD 4123 (AU). MAGUIRE, David, James [AU/AU]; 41 Vine Street, Redland Bay, QLD 4165 (AU). VOROTELIAK, Victor [AU/AU]; 19 Annamarie Street, Rochdale, QLD 4123 (AU).		(74) Agent: KELLY, Robin, Thomas; G R Cullen & Co, G.P.O. Box 1074, Brisbane, QLD 4000 (AU). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FL, FR (European patent), GA (OAPI patent), GB, GB (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: DIAMINE OXIDASE AND ASSAY FOR RUPTURE OF AMNIOTIC MEMBRANE IN PREGNANT MAMMALS (57) Abstract <p>This invention relates to an assay for detection of a form of diamine oxidase which has now been discovered to be present only in amniotic fluid and more especially to detection of amniotic membrane rupture by detection of the amniotic fluid diamine oxidase. The assay for amniotic membrane rupture not only includes the step of detection of the amniotic fluid diamine oxidase but also in distinguishing same from another form of diamine oxidase found in serum. This assay may be carried out on a sample of vaginal fluid from a pregnant female wherein the sample is subjected to the assay to detect the leakage or presence of amniotic fluid diamine oxidase. The invention also relates to purified forms of amniotic fluid diamine oxidase and serum diamine oxidase which is different to amniotic fluid diamine oxidase and found in serum. The invention also includes a method of purification of both forms of diamine oxidase.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LJ	Licchtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

DIAMINE OXIDASE AND ASSAY FOR RUPTURE OF AMNIOTIC MEMBRANE IN
PREGNANT MAMMALS

THIS INVENTION relates to purified forms of Diamine
Oxidase (DAO) and in particular one form of this enzyme
5 found in serum (hereinafter called serum DAO) and another
form of this enzyme found in amniotic fluid (hereinafter
called amniotic fluid DAO). The invention also relates to
methods for preparation of these purified enzyme forms.

The invention also relates to an assay for
10 detection of amniotic fluid DAO in body fluids and in
particular to an assay for diagnosis of rupture of amniotic
membrane or leakage of amniotic fluid through the membrane.

Diamine Oxidase (E.C.1.4.3.6) (hereinafter called
DAO) catalyses the oxidation of diamines such as histamine,
15 putrescine and cadaverine, which yields an aminoaldehyde.
During early investigations the enzyme was believed to only
oxidise histamine: thus the enzyme was initially named
Histaminase by Best and McHenry (1929). Further
investigations proved that the enzyme was capable of
20 oxidation of other diamines such as those listed above. The
nomenclature currently in use, Diamine Oxidase, was later
suggested by Zeller (1965).

Until 1965, the only intracellular mammalian
diamine oxidase that had been purified was pig kidney
25 histaminase (Kapeller-Adler, 1963; and Mondovi, 1964).
Considerable purification of pig kidney histaminase (200- to

240-fold) was obtained by Tabor in 1951. Higher degrees of purification were successively obtained by applying column chromatography and electrophoresis (Mondovi, 1967a; and Uspenskaia, 1958). Diamine oxidase has also been purified from the pig kidney cortex by chromatography on hydroxylapatite and DEAE-Sephadex A-50, and gel filtration through Sephadex G-200 (Bardsley, 1971). This gave an enzyme preparation purified 230-fold with a 35% yield.

AH-Sepharose 4B was used as an affinity sorbent after partial purification of the pig kidney diamine oxidase by means of controlled heating, fractionation with ammonium sulphate and precipitation at pH 5.3. The AH-Sepharose adsorbed inactive proteins in preference to the diamine oxidase. This method provided an enzyme purified 670-fold, but with only a 14% yield (Floris, 1976). Increased yields of the enzyme from pig kidney was achieved by altering the heating conditions used by Floris (1976) on the homogenate, followed by ammonium sulphate fractionation and column chromatography on DEAE-Cellulose. Dialysis of the enzyme against 0.005M phosphate buffer resulted in an electrophoretically homogenous enzyme preparation purified 2400-fold with a 60% yield (Kluetz, 1977b).

Another method developed for purifying diamine oxidase from pig kidney cortex avoided heating the homogenate. The extract obtained after ammonium sulphate fractionation and centrifugation, was subjected consecutively

to column chromatography on DEAE-Sephadex A-50 and hydroxylapatite, with subsequent gel filtration through Sephadex G-150. The enzyme was purified 1350-fold with a 20% yield, and was shown to be homogeneous by SDS-PAGE (Yamada, 1967). To simplify the purification of pig kidney diamine oxidase, an affinity sorbent DAE-Sepharose was introduced by Klimova (1976). An extract of pig kidney cortex homogenate obtained after centrifugation of the ammonium sulphate treated sample was chromatographed on DAE-Sepharose and gave an enzyme preparation purified 200-fold with a 20% yield.

Human kidney diamine oxidase was purified 1800-fold by heating the homogenate, treating it with a mixture of ethanol and chloroform, chromatography on CM-Sephadex, and followed by fractionation with ammonium sulphate and gel filtration through Sephadex G-200 (Shindler, 1976).

Preparation of diamine oxidase from human placenta was achieved by fractionation with ammonium sulphate; chromatography on DEAE-Cellulose and phosphocellulose; and gel filtration through Sephadex G-200 (Smith, 1967). This preparation of diamine oxidase was purified 515-fold, although it still contained haptoglobin and methemoglobin. Paolucci (1971) obtained a 9600-fold purification of placental diamine oxidase with an 8% yield. The proteins of the human placenta were extracted using an acetone powder technique and precipitated with ethanol adsorbed on DEAE-Cellulose; fractionated with ammonium sulphate,

chromatographed on DEAE-Cellulose and subjected to gel filtration through Biogel A-5m. A 4600-fold purification of human placental diamine oxidase was obtained by Bardsley (1974). The methods used in the purification of the enzyme were as those reported for Smith (1967), although a final chromatography step on DEAE-Sephadex or hydroxylapatite was employed which resulted in an increase in specific activity and gave an enzyme which was homogeneous by SDS-PAGE.

Hata (1976) obtained a 1200-fold purification of human placental diamine oxidase obtained by the method described by Bardsley (1974). The polyacrylamide gel electrophoresis pattern of purified human placental diamine oxidase gave a broad band, with the preparation not purified to the same extent as that described by Bardsley (1974). The purification of human placental diamine oxidase was also described by Crabbe (1976), using a modification of the procedure described by Bardsley (1974). Column chromatography incorporated DEAE-Sephadex with ionic strength and pH-gradient elution, together with affinity chromatography on Concanavalin A-Sepharose. This gave a 30,800-fold purification with a 33% yield. Lin (1981) purified placental diamine oxidase in what was referred to as a one-step purification. In this procedure, placentae were homogenized and centrifuged, with the resultant supernatant applied to the affinity gel, cadaverine AH-Sepharose as was previously employed by Baylin (1975b). Elution of the enzyme

was accomplished using chromotropic acid, and provided a 1800-fold purification of the enzyme which was homogeneous by SDS-gel electrophoresis.

5 Plasma diamine oxidase from women in the third trimester of pregnancy was purified 3000-fold with a 25% yield by means of an affinity sorbent sepharose, covalently linked with cadaverine (Baylin, 1975b). The enzyme was eluted from the adsorbent with heparin; electrophoresis by SDS-PAGE presented two protein fractions, one of which
10 displayed the diamine oxidase activity.

Diamine oxidase was isolated from human female amniotic fluid by chromatography on DEAE-Sephadex and affinity chromatography on cadaverine-Sephadex, which was shown by SDS-PAGE to contain only 10% inactive protein
15 (Tufvesson, 1978a). Diamine oxidase from human male serum previously given intravenous heparin (10000 I.U.) one hour before collecting the blood, was isolated by cadaverine-Sephadex affinity chromatography and then by chromatography on DEAE-Cellulose (Tufvesson, 1978b).

20 The enzyme can also be found in kidney and other organs in a variety of animal species. A great deal of time had been devoted to characterization studies of pig kidney (Kapeller-Adler & Macfarlane (1963)) and pig serum (Blaschko, Friedman, et al (1959)) DAO, but the human enzyme (Crabbe,
25 (1979)) has been only poorly characterised.

According to previous studies, there seemed to be

several forms of DAO and these forms exhibited some tissue specificity. Although presence of the enzyme in human placenta and human pregnancy plasma was confirmed by Swanberg (1950), this group was unable to establish any
5 difference between the forms of human placental and pregnancy plasma DAO. Moreover, Tufvesson (1978) could find no difference between amniotic fluid DAO and pregnancy serum DAO, although he suggested that heparin stimulated male serum DAO was different.

10 Four active protein fractions, with molecular weights of 125,000, 250,000, 375,000 and 500,000 daltons were found in preparations of human placental diamine oxidase by Paolucci (1971). The preparation of human placental diamine oxidase obtained by Hata (1976) was purified 1200-fold, and
15 the presence of a broad band on polyacrylamide gel electrophoresis indicated the presence of a contaminant protein which was demonstrated distinctly by immunoelectrophoresis and SDS-PAGE. The molecular weight was calculated to be approximately 300,000 by comparison with a
20 calibration curve by gel filtration and SDS-PAGE. The molecular weight of the subunit was 170,000, which is about two times of 90,000 obtained by Bardsley (1974) and Lin (1981).

25 By the use of gel filtration through Sephadex G-200, polyacrylamide gel electrophoresis in the presence of SDS, or ultracentrifugation, it was demonstrated that a

monomeric, catalytically active form of human placental diamine oxidase had a subunit molecular weight of 70,000 (Crabbe, 1976). This value is close to that reported by Baylin (1975b) for diamine oxidase from pregnancy plasma, which would appear to be a monomer. Sedimentation-equilibrium ultracentrifugation results indicated a single species with a molecular weight of 235,000, which could be explained on the basis of concentration-dependant-aggregation, to be dimeric and tetrameric species which were in equilibrium with each other (Crabbe 1976).

A protein component with a molecular weight of 185,000 was detected by means of gel filtration through Sepharose 6B on purified diamine oxidase from the serum of a man pretreated with heparin (Tufvesson, 1978b). However, a similar technique used on the serum diamine oxidase and amniotic fluid diamine oxidase of pregnant women revealed the presence of two active fractions in both which had native molecular weights of 245,000 and 485,000 (Tufvesson, 1978a, 1978b). Treatment of highly purified diamine oxidase from amniotic fluid with 1% SDS and 1% 2-mercaptoethanol followed by SDS-PAGE revealed the presence of a subunit with an apparent molecular weight of 100,000 dalton (Tufvesson, 1978a). Significantly, Tufvesson determined this apparent molecular weight in the presence of borate buffer which might be expected to lead to an overestimation of the subunit molecular weight. It is important to note here that

Tufvesson did not determine the subunit molecular weight of his serum diamine oxidase preparation. Instead, he assumed that the pregnancy serum and amniotic fluid enzymes were identical presumably because of their identical apparent native molecular weights.

The isoelectric point of purified human amniotic fluid diamine oxidase was determined by measuring the activity of the bands which separated in two active fractions with pI values of 4.0 and 5.8. In considering the results for the isoelectric pH obtained for human placental diamine oxidase, Lin (1981) observed that the purified enzyme separated into 5 major bands and several diffuse bands, with the isoelectric pH of the major bands ranging from 5.3-6.6. In comparison, Crabbe (1976) determined the isoelectric point for human placental diamine oxidase to be 6.5. Thus, there is considerable confusion concerning the apparent isoelectric points of the various forms of diamine oxidase. It is highly likely that the observed isoelectric points are dependant on the method of purification or other factors because of the conflicting results of Lin (1981) and Crabbe (1976).

In respect to the several forms of DAO discussed above, it will be realised that pregnancy greatly modifies all metabolic patterns of histamine, putrescine and polyamines. Histamine and putrescine are produced in large amounts by the fetus. The level of DAO rises in parallel with the levels of histamine and putrescine during pregnancy

(Zeller above). During a normal pregnancy the level of DAO in maternal plasma begins to rise from the second to third month reaching a maximum by the fifth to seventh month and remains at this level until parturition. The level of DAO in plasma falls quite rapidly after parturition (Lorenz, Kusche, 1970). The major function of DAO during pregnancy appears to be to ensure that the levels of the biogenic amines in the placental microcirculation do not become elevated and thus toxic to the developing fetus (Buffoni, 1966).

Premature rupture of the fetal membranes was observed in 6-16% of all pregnancies (Swartz, Napolitani, et al 1969), while another study found the rupture of fetal membranes in 3-14% of all pregnancies was not followed by labour (Larsen, 1979). On rupture of the membranes, Eastman & Hellman (1961) observed that spontaneous labour followed within 24 hours in 80% of patients, with 10% remaining undelivered after a period of 48 hours. The perinatal mortality doubles after a latent period of 24 hours and again after 48 hours (Overstreet & Romney, 1966). Delayed onset of labour carries with it an increased risk of maternal and perinatal infection and mortality (Eastman & Hellman; Kapeller-Adler & Macfarlane; Overstreet above), therefore the accurate detection of ruptured membranes is an important diagnostic aid.

In the mature fetus therefore, early diagnosis of membrane rupture allows for expediting the delivery thereby

reducing infection risk to mother and baby. In the premature infant, accurate diagnosis of membrane rupture is even more important particularly if labour needs to be induced. A reliable, easy method of diagnosis of membrane rupture would be clinically useful to the obstetrician and also cost saving by reducing the need for prolonged and unnecessary hospitalisation. The benefit to those patients resident in the country areas and facing transfer to a tertiary care centre for prolonged periods of hospitalisation away from home and family environment on suspicion of having premature rupture of the membranes would be considerable.

High concentrations of DAO found in amniotic fluid are almost equal to that of maternal blood plasma (Tornqvist, 1971). After rupture of the membranes, DAO is demonstrable in the vagina; wherefore in absence of vaginal bleeding or exudation the measurement of the DAO content of vaginal fluid has been shown to be a reliable method in evaluation of membrane rupture (Ahlmarm, 1944); Elmfors, Tryding, et al (1974); Gahl, Kozina, et al (1982). Besides physical examination, current techniques for establishing the diagnosis of ruptured fetal membranes are (Elmfors, Tryding (1976))

1. Determination of the vaginal pH;
2. Staining for fetal fat globules;
3. Identification of fetal squamous cells or hairs;
4. Examination for typical crystallisation of amniotic

fluid (ferming).

In accordance with Friedman & McElin (1976) any three of the abovementioned methods taken together provide an accuracy of 93% although false-positive and false-negative results are frequent with all laboratory techniques which are applied in diagnosing rupture of the membranes (Larsen above). Dyes and other chemicals have been injected into the amniotic fluid transabdominally and their appearance looked for in the vagina but these techniques are not without risk (Jimsenez-Balderaz E.A. Bol. Med. Hosp. Infant Mex. 1984, 41, P341-4). Measurement of amniotic fluid volume by ultrasound before and after bed rest may be helpful but is not specific (Rudd above).

Measurements of the protein alpha-fetoprotein and the hormones prolactin and human placental lactogen have been investigated by Huber, J.F. et al (Huber, J.F. et al, Are Vaginal Fluid Concentrations of Prolactin, alpha-Fetoprotein and Human Placental Lactogen Useful for Diagnosing Ruptured Membranes, Br. J. Obstet. Gynaecol. 90, 1183-1185) but he found many positive tests in patients whose membranes were intact. This was due in part to the fact that these substances are present in maternal serum and therefore the test is positive when either serum or amniotic fluid or both are present in the vagina.

Rochelson B.C. (Rochelson, B.C., A rapid colorimetric AFP monoclonal antibody test for the diagnosis

of preterm rupture of the membranes. Obstet. Gynaecol. 1987, 69, P163-6) has also found blood and serum to give false positive results with his test for the presence of alpha-fetaprotein in vaginal fluid). Elmfors et al (above), using
5 the information of Tornqvist & Jonassen (above) developed a method for the diagnosis of ruptured membranes by measuring the DAO activity in vaginal fluid. DAO activity is present in amniotic fluid but normally absent from vaginal secretions, presenting a method for diagnosing rupture of the
10 membrane (Elmfors, Tryding et al above; Gahl, Kozina, et al above). The most widely used method for collection of DAO activity in vaginal secretions is the use of blotting paper to collect the secretions and phosphate buffer to elute the enzyme (Elmfors, Tryding above). Wishart, Jenkins et al
15 (1979) also supported the use of the procedure and found an assay to offer useful clinical information. The factors which suggest that the DAO assay may be used as an adjunct to conventional tests in the diagnosis of rupture of membranes have been summarised by Gahl et al (above). However, the
20 major drawback of the assay is that it depends on the measurement of enzyme activity and can give false results in the presence of interfering substances such as:-

1. urine;
2. meconium;
- 25 3. antiseptics;
4. pregnancy serum;

5. seminal fluid;

6. haemoglobin

These substances commonly contaminate the vagina therefore invalidating current methods which are limited by interfering substances, inadequate sensitivity and subjective interpretation of results.

It is therefore an object of the present invention to provide an assay for diagnosis of amniotic membrane rupture or leakage of amniotic fluid which is reliable and alleviates the problems encountered in the prior art assays above.

The invention therefore provides an assay for the detection of amniotic fluid in body fluids and in particular an assay for diagnosis of rupture of the amniotic membranes in pregnant mammals or leakage of amniotic fluid and in particular pregnant women including the step of detecting the presence of amniotic fluid DAO in vaginal fluid and distinguishing same from serum DAO.

In regard to pregnancy in females inflammation of the birth canal and in particular the cervix may cause leakage of maternal serum into the vagina. Maternal serum contains serum DAO and it has now been surprisingly discovered by the process of the present invention that serum DAO may be differentiated from amniotic fluid DAO by appropriate techniques described in detail hereinafter.

When rupture of the amniotic membrane occurs this

causes leakage of amniotic fluid into the vagina with the subsequent result that the vagina will contain amniotic fluid DAO. It is thus evident that if the presence of amniotic fluid DAO may be detected and distinguished from serum DAO then a valuable tool will be provided for early diagnosis of amniotic membrane rupture. This therefore provides a clear demonstration that "breaking of the waters" has occurred and thus false alarms caused by vaginal fluid leakage may be avoided. False alarms are particularly prevalent when vaginal fluid may be leaked or emitted from the vagina after swimming or taking a bath.

It is believed following the development of the present invention that amniotic fluid DAO (hereinafter AF-DAO) is a modified form of serum DAO (hereinafter S-DAO) and that for example AF-DAO may have a surrounding envelope of polysaccharide or amide or alternatively may have a different biological conformation. It is also possible that AF-DAO may comprise S-DAO with a component removed therefrom or added thereto. In any event the present invention is not bound by any particular theory and is solely based on the discovery that S-DAO is indeed a different protein when compared to AF-DAO. This therefore means that S-DAO may be differentiated from AF-DAO by appropriate techniques which include differences in subunit molecular weight or biological activity. However probably the best method of distinguishing between AF-DAO and S-DAO is by the use of immunological

techniques such as RIA, FIA, EIA, ELISA, agglutination including latex beads or chemiluminescence. In this regard therefore development of an appropriate antibody which may be polyclonal or monoclonal in nature would be of assistance in distinguishing S-DAO from AF-DAO. Thus a specific polyclonal or monoclonal antibody for either S-DAO or more probably AF-DAO will be extremely useful in differentiating these proteins.

The present invention therefore can be utilised in the following cases:

(i) where there is premature rupture of the amniotic membrane without blood loss;

(ii) where there is premature rupture of the amniotic membrane with blood loss;

(iii) where there is a lesion of the birth canal and particularly the cervix without rupture of the amniotic membrane;

(iv) where there is no rupture of the amniotic membrane and no lesion; and

(v) where there is rupture as well as a lesion.

In the case of (i) above a test for presence of AF-DAO in the vaginal fluid would be positive and a test for S-DAO would be negative.

In the case of (ii) above tests for AF-DAO and S-DAO would both be positive.

In the case of (iii) above a test for AF-DAO would

be negative and for S-DAO would be positive.

In the case of (iv) above both tests would be negative.

In the case of (v) above both tests would be positive.

It is therefore within the scope of the present invention that diagnosis of one or all of the above cases (i) to (v) are contemplated.

The assay of the invention in a preferred form may include the following steps:

(a) obtaining a sample of vaginal fluid from a pregnant female;

(b) reacting the sample with antibody derived from S-DAO or AF-DAO; and

(c) detection of reactivity by a signal amplification.

The invention may also include within its scope a test system or kit for use with the method described above. this may include S-DAO and/or AF-DAO antibody which is immobilised to an inert surface such as a test tube or other suitable vessel. The antibody which is suitably a monoclonal antibody may be physically or chemically bound to the inert surface.

However, more suitably, the reaction system may include an immunoabsorbed polyclonal antibody for S-DAO and/or AF-DAO immobilised to the inert surface. A further

component of the reaction system may be a tag polyclonal or monoclonal antibody for S-DAO and/or AF-DAO which has a suitable label attached thereto. Upon reaction with AF-DAO or S-DAO with the polyclonal antibody the tag monoclonal antibody may be bound to the AF-DAO or S-DAO antigen and the label subsequently detected by any suitable means as described above. Thus if the label is an enzyme a suitable enzyme substrate may be used. Alternatively RIA, FIA, agglutination chemiluminescence or a dipstick detection may be used depending upon the label.

In regard to the foregoing it will also be appreciated that the term "rupture" may also include within its scope a perforation of the amniotic membrane which does not need to complete rupture or breakdown thereof. In some cases a perforation could well exist in the amniotic membrane resulting in leakage of amniotic fluid but without resulting in complete rupture or breakdown of the membrane.

In another aspect of the invention, there is also provided two forms of DAO that have now been characterized by a variety of physico-chemical methods and that these physico-chemical methods may be used to clearly differentiate between these forms.

One form of DAO located in serum has now been characterized by possessing the following physical properties:

- (i) a subunit molecular weight of approximately

75,000 daltons performed by SDS-PAGE with gels of different acrylamide concentrations;

(ii) a native molecular weight analysis determined by gradient-PAGE or gel filtration chromatography and which revealed a number of species having apparent molecular weights of approximately 120,000; 160,000 and 480,000 respectively.

(iii) isoelectric focusing studies revealed a pattern characteristic of a glycoprotein and with substantive bands with isoelectric points greater than 5.

(iv) analysis of the purified enzyme by electrophoresis on agarose gels and immunofixation with polyclonal antisera revealed multiple bands of activity different to these bands corresponding to amniotic fluid DAO; and

(v) immunoadsorption of the polyclonal antisera raised to amniotic fluid DAO with maternal serum and purified maternal serum removed all reactivity to the maternal serum proteins when tested by immunofixation.

Another form of DAO located in amniotic fluid has also been characterized by possessing the following physical properties:

(i) a molecular weight of approximately 79,000 daltons performed by SDS-PAGE with gels of different acrylamide concentrations (When this preparation was compared with maternal serum DAO on the same plate, it consistently

showed a higher apparent subunit molecular weight by approximately 4,000 daltons);

(ii) a native molecular weight analysis as determined by gradient-PAGE or gel filtration chromatography and which revealed a number of species having apparent molecular weights of 120,000; 160,000 and 480,000 daltons. These values are the same as observed for pregnancy serum DAO. The differences between these values and those obtained by Tufvesson (1978b) can be explained by the presence of an impurity (monoamine oxidase) in his preparation;

(iii) isoelectric focusing studies revealed a pattern characteristic of glycoproteins with bands observed having isoelectric points mainly below 5.0;

(iv) analysis of the purified enzyme by electrophoresis on agarose gels and immunofixation with polyclonal antiserum revealed multiple bands of activity different to those bands corresponding to serum DAO; and

(v) immunoadsorption of the polyclonal antiserum raised to amniotic fluid DAO with maternal serum and purified material serum DAO removed all reactivity to the maternal serum proteins when tested by immunofixation but retained activity to amniotic fluid diamine oxidase.

From the foregoing it will also be appreciated that the invention includes within its scope a method of purification of serum-DAO or AF-DAO wherein serum DAO may be obtained from a suitable source of pregnant serum and AF-DAO

obtained from a suitable source of amniotic fluid.

The serum DAO and AF-DAO may be purified using any suitable method of protein purification such as ion exchange chromatography, gel filtration chromatography, electrophoresis, immunoabsorption, affinity chromatography, electroelution or hydroxylapatite chromatography. However, a preferred purification method includes the following steps:-

(i) passing a preparation of serum-DAO and AF-DAO through a first column capable of binding glycoproteins or proteins having associated therewith carbohydrate groups;

(ii) eluting the bound preparation of AF-DAO and Serum-DAO from the column;

(iii) passing the preparation of Serum-DAO and AF-DAO through a second column having binder or ligand which binds to active sites of AF-DAO and Serum-DAO; and

(iv) eluting the AF-DAO and Serum-DAO from the second column.

In step (i) above the first column may comprise an inert support such as Sepharose (eg Sepharose 4B or Sepharose 6MB) having attached thereto a ligand such as lectins which are plant proteins having high affinity for sugar residues. Suitable examples are concavalin A and wheat germ agglutinin. Concavalin A binds to internal and non reducing terminal alpha-mannosyl residues whereas wheat germ agglutinin binds to terminal N-acetylglucosamine residues.

Particularly preferred inert support ligand

combinations are lentil lectin Sepharose 4B and wheat germ lectin Sepharose 6MB.

5 The starting material which required purification by the abovementioned process may be obtained from pregnancy serum or amniotic fluid as described above and may suitably include a filtration or dialysis step or both before being passed through the first column.

10 Suitable eluants that may be used in step (ii) included carbohydrate molecules or sugars or sugar derivatives such as glucosides and mannosides. Suitable examples are alpha-D-methyl mannoside, alpha-D-methyl glucoside, mannose or glucose.

15 In step (iii) the second column suitably includes an inert support such as Sepharose having attached thereto a ligand which has a terminal free amino group. This is necessary to bind to active sites of the Serum-DAO or AF-DAO so as to form an NH_2 grouping whereby the ligand is bound to the enzyme by electrostatic attraction. Suitable ligands are those bearing the general formula $\text{NH}_2-(\text{CH}_2)_n-\text{NH}_2$ wherein n is 1 to 8. Suitable compounds falling within the scope of this formula are cadaverine (n = 5), putrescine (n = 4) and hexanediamine (n = 6).

25 Suitable eluants that may be utilized in step (iv) include salts of concentrations to IM (e.g. 0.2% NaCl) or heparin. Heparin is preferred because it does not having a denaturing effect as is the case with some salts.

Estimation of the subunit molecular weight of both the AF-DAO and S-DAO is suitably carried out electrophoretically using sodium dodecyl sulphate (SDS) and mercaptoethanol. The latter reagent or any other suitable reagent may be used to break any disulphide bridges occurring in the proteins and SDS or other suitable reagent is used to bind to the protein in nonpolar sections thereof so that the molecule has a net overall electric charge suitable for migration in an electric field.

10 EXPERIMENTAL

DAO was purified by the process of affinity chromatography and gel filtration. All chromatographic procedures were performed at 2-8°C unless stated otherwise.

Initially the whole serum and amniotic fluid were passed through glass wool; filtered fractions were then applied onto a Con-A-Sepharose column (Pharmacia, Cat. No. 17-0440-01); equilibrated with the wash buffer as follows:-

20mM Tris/HCl, pH 7.4

0.5M NaCl

20 1mM MnCl_2

1mM CaCl_2

Filtered amniotic fluid or serum were loaded onto the Con-A-column and contaminant proteins eluted with the wash buffer. The bound protein fraction was eluted with the following buffer system;

50mM alpha-methyl-D-glucoside

(SIGMA, Cat No. M 1379)

20mM Tris/HCl, Ph 7.4

Activity of the fractions was determined with fractions displaying the highest activity being pooled.

5 DAO activity was measured by the modified procedure of Gahl et al (1982). The activity was determined by incubating 0.5ml of eluate with 0.1ml of (14 C) putrescine dihydrochloride (109mci/mmol, Amersham Laboratories, Code CFA. 301) in 1.5ml of 1/15M phosphate buffer (pH7.5). The

10 reaction mixture was incubated for 30 minutes at 55°C, after which the reaction was terminated by the addition of 0.2ml 10mM guanidine hydrochloride (Sigma; Cat. No. 64505). To the reaction mixture, 10ml of scintillation grade Toluene (Packard; Cat. No. 6013909) containing 0.5% Butyl-PBD

15 (Packard; Cat. No. 6002154) was added; the cocktail shaken for 10-15 min. then placed into -70°C for 30 min. Blanks were run either with buffer alone or with maternal serum and amniotic fluid in the presence of 10mM guanidine hydrochloride. The organic phase was transferred to new
20 scintillation vials and counted on the LKB Rack Beta. The

second state of purification was based upon the binding of DAO to the substrate cadaverine (SIGMA Cat. No. C8382), which was coupled to CH-Sepharose-4B (Pharmacia, Cat. No. 17-0460-01) using the coupling reagent carbodiimide (SIGMA, Cat. No. E6383).
25 Contaminant proteins were eluted from the column with the following buffer system:

0.2M NaCl

20mM Tris/HCl, pH 7.4

DAO was consequently eluted from the column with Heparin; 1000 Units/ml (Commonwealth Serum Laboratories).

5 Fractions with the highest activity were pooled and concentrated against 20mM Tris/HCl pH 7.4 using Amicon concentrators (Amicon, Prod. No. 4208). Concentrated fractions were stored at -70°C in the presence of glycerol (40% v/v).

10 Electrophoresis was performed in the presence of SDS (SIGMA Cat. No. L4509) and 2-Mercaptoethanol (Biorad, Cat. No. 161-0710) by the method described by Laemmli (1970).

Gels were prepared from the following stock solutions: 29.2g acrylamide (Gradipore, Prod. No. RE-100) and
15 0.8g Bis (Gradipore, Prod. No. RE-180) in a total volume of 100mls. This solution was filtered through Whatmans No. 1 and stored at 20-25°C in the dark. The buffers used in making the gels are as follows: The resolving gel was composed of 1.5M Tris/HCl, pH 8.8 and the stacking buffer was
20 0.5M Tris/HCl, Ph 6.8. The sample buffer consisted of the following:

12.5%(v/v) 0.5M Tris/HCl pH 6.8

10%(v/v) Glycerol

20%(v/v) of 10%(w/v) SDS

25 5%(v/v) 2-Beta-Mercaptoethanol

2.5%(v/v) of 0.05%(w/v)

Bromophenol blue

50% distilled water

Proteins were diluted 1/2 to 1/4 with sample buffer and heated at 95°C for 5-10 minutes.

5 The standard proteins were obtained from Pharmacia (Low molecular weight calibration kit, Cat. No. 17-0442-010).

The subunit molecular weights of serum and amniotic fluid DAO were determined by comparing their mobilities on gels with the protein standards.

10 Serum DAO and amniotic fluid DAO were also purified by the process of affinity chromatography as previously described by Klimova et al (1976). The procedure was based upon the binding of DAO to 1,6-hexanediamine (Pharmacia; Cat. No. H2381), a diamine substrate for DAO, which was coupled to
15 Sepharose 4B (Pharmacia; Cat. No. C1150) via the spacer arm adipic dihydrazide (Pharmacia; Cat. No. A0368). Prior to column application, samples of amniotic fluid and maternal serum were dialysed for 2 hours against two changes of 0.01M phosphate buffer (pH 7.6) followed by two changes of
20 distilled water. Contaminant proteins were removed from the column with 0.01M phosphate buffer (pH 7.6); amniotic fluid DAO was eluted with 1.0N NaCl, and serum DAO eluted with 1.0N NaCl and 0.2M phosphate buffer (pH 7.6). All chromatographic procedures were performed at 4°C. DAO activity was measured
25 by the procedure of Gahl et al (1982) as described previously. Samples with the highest activity were pooled

and dialysed against three changes of 0.01M phosphate buffer (pH7.6) then three changes of distilled water over a period of 2 hours. Upon completion of dialysis, dialysed samples were lyophilised and resuspended to a concentration of 10g/l prior to electrophoresis.

Protein estimations were performed during each stage of purification using the Bio-Rad Protein Assay (Cat. No. 500-0001).

Protein electrophoresis was performed on Titan gels (Helena Laboratories; Cat. No. 3046) and Beckman Paragon gels (Lot No. M70 7019). Protein solutions of 2-5ul were applied to the gel and electrophoresed at 100V for 30 min. on Beckman plates; and at 250V for 22-25 min. on Titan gels. Protein migration on Titan gels was observed by adding bromophenl blue (BDH Chemicals; Prod. No. 20015) to the amniotic fluid or maternal serum sample. Upon completion of electrophoresis, the gel was removed and placed into 10% picric acid solution for 10-15 min. Gels were air-dried, stained in Coomassie Brilliant Blue R-250 (Bio RAD; Cat. No. 161-0406) destained and dried at 60 degrees C. The destaining solution consisted of glacial acetic acid, methanol and distilled water in the ratio of 1:1:8.

Measurement of protein activity was performed on completion of electrophoresis; gel slices of 3x5mm were removed and suspended in 0.01M phosphate buffer (pH7.6). The gel strips were incubated for a period of 1hr at 37 degrees C

then for 24hrs at 4 degrees C, following which the activity was measured by the procedure described above.

Guinea pig antihuman amniotic fluid DAO was prepared by subcutaneously injecting a mixture of amniotic fluid DAO (0.1mg/ml) and Freund's "complete" adjuvant (Commonwealth Serum Laboratories) in a ratio of 1:1. The booster injections utilised Freund's "incomplete" adjuvant, the first was given at 6 weeks, the second at 9 weeks. Blood was collected from the ear veins and the titre of the antiserum was tested at 9 weeks. At 16 weeks 3-5ml of blood was collected by cardiac puncture from one guinea pig. One guinea pig was sacrificed so that 10-15ml of blood was collected. Adsorption of nonspecific antisera was performed by treating the antiserum with serum DAO and maternal serum in the ratio 50:3:1. The treated antiserum was incubated at 37 degrees C for 1 hr then at 4 degrees C for 10 days. Once centrifuged, the immunoabsorbed supernatant was stored at -70 degrees C until required. The specificity of the antiserum was further tested by performing immunofixation against maternal serum, human amniotic fluid and purified maternal serum DAO.

ISOELECTRIC FOCUSING

Reagents

Pharmalyte (3-10)	(PHARMACIA)
Servalyte (4-9)	(SERVA)
Gelbond	(FMC)

Gel Suspension

0.3g Agarose IEF (PHARMACIA)
3.0g Sucrose (AJAX)
27.0ml Distilled water

5

Gel Fixative

5% Sulphosalicylic acid (AJAX)
10% Trichloroacetic acid (TCA) (BDH)

10

Staining Solution

0.25% Coomassie Brilliant Blue R-250
Prepare the dye in destaining solution and filter through
Whatman no. 1 filter paper before use.

Destaining Solution

15

30% Methanol
10% Acetic acid

pI Calibration Kits

Low pI Calibration kit (2.5-6.5) (PHARMACIA)
Broad pI Calibration kit (3-10) (PHARMACIA)

20

Electrode Buffers

Anode buffer: 0.05M Sulfuric acid (H_2SO_4) (BDH)
Cathode buffer: 1M NaOH
Electrode buffer strips (PHARMACIA)

Procedure for Isoelectric Focusing

25

The LKB Multiphor IEF system was utilized for all
electrofocusing studies. Agarose gels were prepared with

ampholines to give pH ranges of 4-9 and 3-10 respectively. Agarose gels were prepared on gelbond which was clamped with the casting mould onto the levelling plate; the gelbond was pre-heated using a hair drier prior to the application of the gel suspension. Before addition of ampholines, the gel suspension was heated under a gas flame until all components had dissolved; the temperature of the suspension was monitored and the ampholines added to the mixture once the temperature had fallen to 75°C. The gel suspension was poured onto the pre-heated casting tray and the bubbles removed with a syringe needle. The gels were allowed to polymerize at R.T. for 30-40min then stored at 4°C for a minimum period of 1hr before use. The cast gel was placed onto the cooling plate (pre-cooled to 9°C) with an even thin film of water separating the gel and cooling plate. The electrode strips were firstly blotted on filter paper to remove excess moisture, then applied onto the gel and pressed along their entire surface to ensure proper contact with the gel surface. The electrofocusing lid was connected, ensuring proper contact between the electrodes and buffer strips, and the gel was pre-focused for 20 min at 1500V, 5W, 150mA. Upon completion of pre-focusing, Samples were applied to the gel surface into the wells of the plastic sample template (PHARMACIA). Volumes of 10-25ul were applied for both the protein samples and pI markers (reconstituted in 0.1ml of distilled water). The electrofocusing lid was re-connected

and the samples allowed to move into the gel at 1500V, 5W, 150mA for 20min. The electrofusing lid was removed, the template was blotted with filter paper and removed; the samples were then further focused for a period of 1hr at 1500V, 10W, 150mA. Upon completion of focusing, the gel was immediately placed into fixative for 30min, followed by 2x30min washes in destaining solution. The gel was then dried by placing filter paper onto the gel and glass plates as weights for 30min; the gel was then dried to completion using a hair drier. The gel film was then placed into staining solution for 10-15min then destained until a clear background was achieved. Finally, the gel was dried with a hair drier for a permanent recording of the gel.

AGAROSE GEL ELECTROPHORESIS

Agarose Gels

Beckman Paragon IFE Gels	(BECKMAN)
Agarose	(LKB)

Barbital Buffer

15g Barbituric acid	(BDH)
47.5g Sodium barbitone	(BDH)
23g Tris	

Dissolve barbituric acid and sodium barbitone in 1.0l of boiling distilled water. Add tris and adjust volume to 4.0l; adjust pH to 8.8 with 1M HCl.

Procedure for Agarose Gel Electrophoresis

Agarose gels were prepared by adding agarose powder (1% w/v) to barbital buffer and boiling the solution on a hot plate; the solution was mixed until the agarose had dissolved. The agarose was then cooled (to approximately 0°C) and poured into a 10ml syringe with a 16-gauge needle and applied to the gel casting assembly (pre-heated at 55°C) which consisted of 10x10cm glass plates separated by a 0.5mm spacer and Gelbond. The gel was allowed to set at 4°C for 1hr prior to use. Proteins samples of 3-5µl were applied to the gel surface with the aid of a template. Bromophenol blue prepared in distilled water (0.1%) was added to samples of maternal serum or amniotic fluid as a marker. Electrophoresis was performed using the beckman Electrophoresis System and the Zip-Zone electrophoresis chamber and cooling plate (HELENA). Proteins were electrophoresed for 30min at 100V constant voltage using the 2103 Power Supply (LKB). Upon completion of electrophoresis, proteins were fixed in 50% methanol, 10% acetic acid for 30min. The gel was then dried with a hair drier and stained according to the IEF staining procedure discussed herein.

Activity Studies Performed With Agarose Gels

Following the completion of protein electrophoresis on the agarose gel, sections of the gel of 3x5mm were removed with a scalpel and placed into a 5ml glass test-tube. The gel sections were incubated in the presence of 0.5ml of 1/15M

sodium phosphate buffer, pH 7.4, for a period of 7 days at 4°C. The enzyme activity of each section was then measured by radioenzymatic analysis of the sample buffer.

IMMUNOFIXATION

5 Immunofixation was performed on agarose gels using guinea pig anti-human amniotic fluid DAO antisera. All antisera were immunoabsorbed with maternal serum and purified maternal serum DAL; the mixture was incubated in an eppendorf tube for 1hr at 37°C then incubated at 4°C for 1 week. The
10 antisera were centrifuged for 10min at 5000g in a Beckman Centrifuge; the supernatant was collected and stored at -70°C in 0.1-0.2ml aliquots. Proteins were electrophoresed on agarose gels as previously described prior to immunofixation. Upon completion of electrophoresis, both immunoabsorbed and
15 non-absorbed antisera were applied to cellulose acetate strips which were then placed onto the gel surface corresponding to the area of protein electrophoresis. The gels were then incubated at R.T. for 1hr in a humidity chamber; the cellulose acetate strips were removed and the
20 gel was put through the wash and dry process. This process involved washing the gel for 3 x 15min cycles in saline, then drying the gel after each wash cycle for 10-15min by placing filter paper and a 500g weight onto the gel. On completion of the third saline wash, the gel was completely dried with a
25 hair drier and stained as previously described for agarose gels. For a direct comparison of the immunofixation to the

protein patterns, the outer tracks of the agarose gel were cut out and stained for proteins.

IMMUNOPRECIPITATION

To assess the extent DAO activity was removed from maternal serum and amniotic fluid by antibody the fluids were incubated with different volumes of polyclonal antisera. To 0.5ml of amniotic fluid and maternal serum, 0.01-0.1ml of the antibody was added and incubated for 2hr at 37°C in eppendorf tubes. Control tubes were also prepared with 0.01-0.1ml of 1/15M phosphate buffer pH 7.4 supplemented for the antibody. The tubes were then centrifuged at 5000g for 10min on a Beckman Centrifuge and the supernatants collected and tested for enzyme activity by radioenzymatic analysis.

Using the procedures previously described to purify DAO (affinity sorbent DAH-Sepharose as introduced by Klimora and co-workers 1976) resulted in an approximately 11-fold purification for amniotic fluid DAO (Table 2) and a 40-fold purification for maternal serum DAO (Table 3). To examine the effect of phosphate buffer on DAO activity, different concentrations of the phosphate salts were introduced to the radioenzymatic procedure to observe their effect on DAO activity. The results displayed in Fig. 1 show that in the presence of increasing levels of phosphate, there is a considerable loss in enzyme activity. There is an approximate 20% loss in DAO activity in amniotic fluid and maternal serum when incubated in the presence of 0.2M

phosphate buffer (elution buffer for DAH-Sepharose affinity chromatography).

Tables 4 and 5 represent the various stages of DAO purification from maternal serum and amniotic fluid using the second purification procedure. The first stage in this purification process utilized the properties of A-Sepharose, enabling it to bind glycoproteins. In particular, to isolate the carbohydrate containing components from whole serum and amniotic fluid prior to further purification processes. Pool fractions of both fluids were applied to Con A-Sepharose and the contaminated proteins washed through the column; no DAO activity was observed in the wash fraction as determined by radioenzymatic analysis. Elution of the fraction containing DAO activity was performed using the glycoside methyl-D-glucosidase. The enzyme activity was eluted in a broad elution peak with poor recovery of the activity; approximately 2.2% for amniotic fluid and 2.7% for maternal serum. Those fractions demonstrating the highest activity were pooled, concentrated and loaded on the Cadaverine-Sepharose column. Contaminant proteins were removed from the Cadaverine-Sepharose column with the equilibration buffer; radioenzymatic analysis of the contaminant fractions revealed no DAO activity. The elution of the DAO fraction was performed with 20mM Tris 1M NaCl which resulted in the elution of a well defined peak. The results of the radioenzymatic assay revealed that the extent of enzymatic

activity recovered was approximately 30% for amniotic fluid and 55% for maternal serum. The purification of amniotic fluid and maternal serum post Cadaverine-Sepharose affinity chromatography had resulted in a considerable loss in enzyme activity, the causative factor of which was believed to be the high salt concentration of the elution buffer. To examine the effect of salt on DAO activity, an experiment was performed incorporating varying concentrations of NaCl in 1/15M phosphate buffer for the radioenzymatic assay, and observing the outcome of the DAO activity in maternal serum and amniotic fluid. In observing the salt effect on DAO (Fig. 2), an increase in the level of salt present in the buffer had a considerable effect on the activity of the enzyme; with an approximate loss of 80% for both amniotic fluid and maternal serum DAO in the presence of 1M NaCl. The removal of the salt by dialysis or with the stirred cell allowed on an average for 10% recovery in enzyme activity, with an overall loss of 70% for both fluid proteins. To eliminate the use of salt in the elution buffer, heparin was substituted for NaCl to elute DAO from the Cadaverine-Sepharose affinity column. Upon removal of the contaminant proteins with the wash buffer, a step-wise gradient of elution buffer containing 100-1000 Units of heparin was introduced to the affinity column. Radioenzymatic analysis of the fractions collected from the heparin elution confirmed that the DAO activity was confined to the peak resulting from

the elution with 1000U of heparin. The addition of the elution buffer with 1M NaCl to the affinity column after heparin elution, resulted in no further elution of DAO activity, although a small contaminant protein peak was observed. The results for the recovery of enzyme activity revealed an approximate level of 45% for amniotic fluid (TABLE 6) and 72% for maternal serum (TABLE 7). The presence of heparin, as was determined by the radioenzymatic assay; had no effect on the overall enzyme activity when incubated in the presence of amniotic fluid and maternal serum. To evaluate the extent of protein loss due to the membranes in the stirred cells, purified amniotic fluid and maternal serum DAO were diluted in 20mM Tris (pH 7.4) and the enzyme activity was determined both prior to and following sample concentration. The results revealed on average a 8% loss in enzyme activity due to probable protein retention.

ELECTROPHORESIS

Figure 3 shows the electrophoretic patterns on a 10% SDS polyacrylamide gel of purified amniotic fluid and maternal serum DAO eluted with 1M NaCl from the Cadaverine-Sepharose affinity column. This was compared to maternal serum DAO purified by DAH-Sepharose affinity chromatography. The subunit molecular weight estimated from the calibration curve constructed by plotting the log M.W. against protein migration, was determined to be approximately 79,000 for amniotic fluid DAO and 75,000 for maternal serum DAO. A

comparison by SDS-PAGE of DAO purified by DAH-Sepharose revealed a number of contaminant proteins; moreso than when compared to the amniotic fluid and maternal serum DAO purified by Cadaverine-Sepharose affinity chromatography and eluted with 1M NaCl. A high molecular weight contaminant was present in the purified preparations of amniotic fluid and maternal serum from Cadaverine-Sepharose chromatography.

Comparison with the purified fractions of DAO from DAH-Sepharose chromatography revealed a greater degree of contamination, moreso for maternal serum DAO (Fig. 3). The contaminant proteins were removed by the process of gel-filtration HPLC, no enzyme activity was observed in the contaminant fractions.

In the case of Fig. 4, electrophoresis was performed on a 12.5% polyacrylamide gel; comparing purified amniotic fluid and maternal serum DAO eluted with heparin from the Cadaverine-Sepharose affinity column. Fewer contaminant proteins were observed in the purified DAO fractions eluted with heparin when compared to those eluted with 1M NaCl as shown in Fig. 3. Estimation of the subunit molecular weight from the calibration curve revealed an amniotic fluid DAO band at 79,000 and a maternal serum DAO band at 75,000. Continuous PAGE was performed on a 7.5% polyacrylamide gel to assess the subunit molecular weight of amniotic fluid and maternal serum DAO eluted with heparin from the Cadaverine-Sepharose affinity column and put

through the HPLC gel permeation column. The results for amniotic fluid and maternal serum electrophoresed by continuous PAGE shown in Fig. 5 revealed that a clear difference exists in the subunit structure of the two purified proteins. When the subunit molecular weights were estimated from the calibration curve constructed using the LMW prestained standards, the subunit molecular weight for amniotic fluid DAO was determined to be 79,000, and for maternal serum DAO, 75,000. Determination of the native molecular weight of amniotic fluid and maternal serum DAO by gradient PAGE and HPLC gel permeation revealed that DAO exists as a complex, multisubunit protein. The native molecular weight as was assessed by gradient PAGE for both amniotic fluid DAO and pregnant serum DAO (Fig. 6) revealed molecular weights of 120,000; 160,000 and 480,000. Estimations of the native molecular weights for both proteins by HPLC gel permeation studies also revealed a number of different peaks which displayed enzyme activity and molecular weights approximately the same as those described above as estimated from a calibration curve constructed using gel filtration standards for both amniotic fluid DAO and maternal serum DAO. Similar results were obtained for both amniotic fluid and maternal serum DAO purified by Cadaverine-Sepharose affinity chromatography and eluted from the column with heparin or 1M NaCl (Fig. 6). Variations in the results obtained for the determination of native molecular weight was

observed for protein solutions stored for periods of more than 2 weeks at -70°C .

ISOELECTRIC FOCUSING

As shown in Fig. 7, maternal serum DAO eluted with heparin (track 4) and 1M NaCl (track 7) from the Cadaverine-Sepharose affinity column and put through the HPLC gel permeation column were analysed on an agarose IEF gel with Pharmalyte as the ampholine source. Maternal serum DAO was separated into at least 4 major and many diffuse bands; the isoelectric pH of the major bands for maternal serum DAO ranged from 5.3-5.6, with a large diffuse and acidic tail. A faint diffuse region at 5.75-5.8 was also observed. Amniotic fluid DAO was eluted with heparin (track 6) and 1M NaCl (track 3; faint bands) from the Cadaverine-Sepharose column and put through the HPLC gel permeation column. Amniotic fluid DAO resolved into at least 4 faint bands; the isoelectric pH of these bands ranged from 4.6-5.0. The results of Fig. 8 also showed differences in the separation of amniotic fluid DAO (track 3) and maternal serum DAO (track 4), both of which were eluted from the Cadaverine-Sepharose affinity column with 1M NaCl and put through the PHLC gel permeation column and electrofocused with servalyte as the ampholine source. The protein pattern in track 5 (Fig. 8) is that of maternal serum DAO and track 6 is amniotic fluid DAO (faint), eluted from the DAH-Sepharose affinity column with 0.2M phosphate buffer; amniotic fluid was then further

purified by gel filtration through Sephadex G-200.

AGAROSE GEL ELECTROPHORESIS

Amniotic fluid and maternal serum DAO eluted with 1000U of heparin from the Cadaverine-Sepharose affinity column were electrophoresed on a 1% agarose gel as shown in Fig. 9. Maternal serum DAO separated into 3 distinct bands; one band migrated in close proximity to transferrin, the second band migrated in the vicinity of C3, and the third band was located near the origin. Immunofixation performed on purified maternal serum DAO with anti-human C3 (BECKMAN) and anti-human transferrin (KALLESTAD) revealed no visible cross-reactivity with either antisera. Electrophoresis of purified amniotic fluid DAO (heparin eluted) also separated into 3 bands (Fig. 9); the first band migrated in the region between albumin and prealbumin, the second band was observed to a broad band which migrated in the alpha 2-beta globulin region, the third band was observed in the vicinity of the C3 band. Enzyme activity studies were performed on purified amniotic fluid and maternal serum DAO (eluted with 1M NaCl and heparin) electrophoresed on agarose gels (Fig. 10). Results for amniotic fluid DAO as shown in Fig. 10 revealed two areas of enzyme activity which corresponded to the 2 bands observed with protein staining (Fig. 9). Lower levels of enzyme activity were also observed with the small amniotic fluid DAO band which had migrated in the region between albumin and prealbumin. This band in particular was more

evident in samples of amniotic fluid DAO eluted with heparin, or in samples stored for long periods at -70°C . Enzyme activity studies performed on maternal serum DAO also revealed a number of areas of enzyme activity corresponding to the protein pattern shown in Fig. 9. The majority of the activity for maternal serum DAO was distributed in a broad area; the highest levels of enzyme activity were associated with the band closest to the origin and the band which had migrated in the region of C3. The maternal serum DAO band observed in the region of transferrin displayed variable levels of enzyme activity, which may be accounted for due to the diffuse nature of the band.

IMMUNOFIXATION

Immunofixation studies were performed using guineapig antihuman amniotic fluid DAO antisera; raised against DAH-Sepahrose and Sephadex G-200 purified amniotic fluid DAO. Immunofixation of amniotic fluid and maternal serum DAO with guineapig anti-human amniotic fluid DAO displayed cross-reactivity to both purified enzymes as is shown in Fig. 11. Incubation of the antisera in the presence of maternal serum and maternal serum DAO in the ratio of 50:1:0.3, produced a precipitate which was removed upon centrifugation. The immunoadsorbed antiserum was tested against heparin eluted amniotic fluid and maternal serum DAO.

Results of immunofixation performed on Bechman agorose plates with antihuman amniotic fluid DAO antisera

which was immunoabsorbed with maternal serum and serum DAO in the ratio of 50:3:1 are shown in Figure 12. Immunofixation studies with amniotic fluid DAO and serum DAO showed a reaction only with amniotic fluid DAO, with all the activity to serum DAO removed (Fig.4.). The reactivity towards amniotic fluid DAO was directed at the broad band in the region of C3 and to the band located between albumin and prealbumin. Some degree of reactivity was also directed against the amniotic fluid protein band in the alpha 2-beta globulin region.

IMMUNOPRECIPITATION

To examine the specificity of the polyclonal antisera to DAO, maternal serum and amniotic fluid were incubated in the presence of various volumes of polyclonal antisera. From the results shown in Fig. 13, pre-adsorbing maternal serum and amniotic fluid with the polyclonal antisera resulted in the removal of enzyme activity due to the probable formation of antibody-antigen complexes which were removed upon centrifugation.

ASSAY OF VAGINAL FLUID SPECIMENS

Vaginal fluid specimens were collected from two healthy pregnant women who had no clinical evidence of rupture of the amniotic membranes and from one pregnant woman in whom rupture of the membranes was thought to have occurred. A vaginal speculum was passed and fluid collected from the posterior vagina with a sterile syringe. Samples of

these fluids (6 μ l) were applied to separate wells on an agarose plate (Titan). After electrophoresis, immunoabsorbed polyclonal anti amniotic fluid diamine oxidase specific antiserum was applied to cellulose acetate strips which were overlaid on the fluid electrophoresis pulterus. After incubation for 30 minutes in a humidity chamber at room temperature, the srips were removed and the gels were serially dehydrated and washed three times with saline (0.9 G1100mls) and the remaining immunoprecipitates were visualized with Coomassie Blue.

No immunoprecipitate as shown in FIG 14 was seen in the specimens from the normal women (lanes 1 and 2). Strong immunoprecipitation was observed in the β -legion of the electrophorelogram prepared from the pregnant woman who had clinical evidence of rupture (lane 3) confirming this diagnosis.

THE REFERENCES AS CITED IN THE SPECIFICATION ARE AS FOLLOWS:

Ahlmark, A. (1944). Studies on the Histaminolytic Power of Plasma with Special Reference to Pregnancy. Acta. Physiol. Scand. 9 [Suppl. 18].

Bardsley, W.G., Ashford, J.S. and Hill, C.M. (1971). Synthesis and Oxidation of Aminoalkylonium Compounds by Pig Kidney Diamine Oxidase. Biochem. J. 122: 557-567.

Bardsley, W.G., Crabbe, M.J.C. and Scott, I.V. (1974). The Amine Oxidases of Human Placenta and Pregnancy Plasma. Biochem. J. 139: 169-181.

Baylin, S.B., Abeloff, M.D., Wieman, R.C., Tomford, J.W. and Ettinger, D.S. (1975a). Elevated Histaminase (Diamine Oxidase) Activity in Small-Cell Carcinoma of the Lung. N. Engl. J. Med 293: 1286-1290.

Baylin, S.B. and Margolis, S. (1975b). Purification of Histaminase (Diamine Oxidase) From Human Pregnancy Plasma by Affinity Chromatography. Biochem. Biophys. Acta. 397: 294-306.

Best, C.H. (1929). The Disappearance of Histamine From Autolysing Lung Tissue. J. Physiol. (LONDON). 67: 256-263.

Blaschko, H. (1963) Amine Oxidase. In. The Enzymes, ed. by J.B. Summer and K. Myrbock, Academic Press, Inc., New York. 3: 337-351.

Buffoni, F. (1966). Histamine and Related Amine Oxidases. Pharmacol. Rev. 18: 1163-1199.

Crabbe, M.J.C., Waight, R.D., Bardsley, W.G., Barker, R.W.,
Kelly, I.D. and Knowles, P.F. (1976). Human Placental
Diamine Oxidase: Improved Purification and Characterization
of a Copper- and Manganese-Containing Amine Oxidase with
5 Novel Substrate Specificity. Biochem. J. 155: 679-687.

Elmfors, B., Tryding, N. and Tufvesson, G. (1974). The
Diagnosis of Ruptured Fetal Membranes by Measurement of the
Diamine Oxidase Activity in Vaginal Fluid. J. Obst. Gynecol.
10 Brit. Commonwealth 81: 361-362.

Elmfors, B. and Tryding, N. (1976). Date of confinement
Prediction from Serum Diamine Oxidase Determination in Early
Pregnancy. Br. J. Obstet. Gynecol. 123: 605-609.

Floris, G., Fadda, M.B., Pellegrini, M., Corda, M. and
Finazzi-Agro, A. (1976). Purification of Pig Kidney Diamine
Oxidase by Gel-Exclusion Chromatography. FEBS Letters 21:
15 56-63.

Friedman & McElin. Diagnosis of ruptured fetal membranes,
20 Am. J. Obstet. gynaecol. 48, 172, 1976.

Gahl, W.A., Kozina, T.J., Fuhrmann, D.D. and Vale, A.H.
25 (1982a). Diamine Oxidase in the Diagnosis of Ruptured Fetal
Membranes. Obstet. Gynecol. 60(3): 297-304.

Gahl, W.A. Raubertas, R.F., vale, A.M. and Galubjatnikov, R.
(1982b). Maternal Serum Diamine Oxidase in Fetal Death and
30 Low Birthweight Infants. Br. J. Obstet. Gynaecol. 89: 202-
207.

Hata, A. (1976). Purification and Some Properties of Diamine
Oxidase from Pig Kidney and Human Placenta. Bull. Tokyo Med.
35 Dent. Univ. 23: 63-70.

Kapeller-Adler, R. and MacFarlane, H. (1963). Purification and Identification of Hog-Kidney Histaminase. *Biochim. Biophys. Acta* 67: 542-565.

5

Klimova, G.I., Gromova, L.N. and Gorkin, V.Z. (1976). Sorbent for the Purification of Diamine Oxidase by Affinity Chromatography. *Appl. Biochem. Micr. (MOSCOW)*. 12: 614-618.

10

Kluetz, M.D. and Schmidt, P.G. (1977). Diamine Oxidase: Molecular Weight and Subunit Analysis. *Biochem. Biophys. Res. Comm.* 76: 40-45.

15

Laemmli, U.K. (197). Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4. *Nature* 227: 680-685.

20

Lin, C.-W., Kirley, S.D. and St. Pierre, M. (1981). Tumor and Placental Histaminase: Affinity Chromatography, Purification and Characterization of the Placental Enzyme. *Oncodev. Biol. Med.* 2: 267-280.

25

Larsen, Premature rupture of the membranes, *Br. Med. J.*, 1, 1165, 1979.

Lorenz, Kusche, et a, Diaminoxidase, methoden den enzymatischen anayse, 2nd Ed.

30

Mondovi, B., Rotilio, G., Finazzi-Agro, A. and Scioscia-Santora, A. (1964). Purification of Pig Kidney Diamine Oxidase and Its Identity with Histaminase. *Biochem. J.* 91: 408-415.

35

Mondovi, B., Rotilio, G., Costa, M.T., Finazzi-Agro, A., Chiancone, F., Hansen, R.E. and Beinert, H. (1967). Diamine Oxidase From Pig Kidney. Improved Purification and Properties. J. Biol. Chem. 242: 1160-1167.

5

Overstreet & Romney, Am. J. Obstet. Gynaecol., 96, 1036, 1966.

10

Paolucci, F., Cronenberger, L., Plan, R. and Pacheco, H. (1971). Purification et Proprietes de la Diamine: Oxygene Oxydo-Reductase du Placenta Humain. Biochimie 53: 735-749.

15

Shindler, J.S. and Bardsley, W.G. (1976). Human Kidney Diamine Oxidase: Inhibition Studies. Biochem. Pharm. 25: 2689-2694.

Smith, J.K. (1967). The Purification and Properties of Placental Histaminase. Biochem. J. 103: 110-119.

20

Swanberg, H. (1950). Histaminase in Pregnancy with Special Reference to Its Origin and Formation. Acta Physiol. Scand. 23 (Suppl 79): 1-69.

25

Swartz, Napolitani, et al, Controversy in obstetrics and gynecology, Ed. D.E. Reid & T.C. Bacon, Saunders, Philadelphia, London, Toronto, 46, 1969.

30

Tornqvist, A., Jonassen, F., Johnson, P. and Fredholm, A. (1971). Studies on Diamine Oxidase Activity During Pregnancy. Acta Obstet. Gynec. Scand. 50: 79-82.

Tufvesson, G. (1978a). Purification and Properties of Human Amniotic Fluid Diamine Oxidase. Scand. J. Clin. Lab. Invest. 38: 463-472.

35

Tufvesson, G. (1978b). A Comparison Between Diamine Oxidases From Human Post-Heparin Blood Serum, Pregnancy Blood Serum and Amniotic Fluid. Scand. J. Clin. Lab. Invest. 38: 473-476.

5

Uspenskaia, V.D. and Goriachenkova, E.V. (1958). The Purification of Diamine Oxidase by Electrophoresis. Biokhimiya 23: 199-205.

10

Wishart, H.M., Jenkins, D.T. and Knott, M.C. (1979). Measurement of Diamine Oxidase Activity in Vaginal Fluid-An Aid to Diagnosis of Ruptured Fetal Membranes. Aust. N.Z. J. Obstet. Gynaec. 19: 23-24.

15

Yamada, H., Kumagai, H., Kawasaki, H., Matsui, H. and Ogata, K. (1967). Crystallization and Properties of Diamine Oxidase From Pig Kidney. Biochem Biophys. Res. Comm 29: 723-727.

20

Zeller, E.A. (1965). Identity of Histaminase and Diamine Oxidase. Fed. Proc. 24: 766-768.

DESCRIPTION OF FIGURES 1-14

Fig. 1. Phosphate salt inhibition of amniotic fluid DAO (O) and maternal serum DAO (X). The increasing phosphate salt concentrations were substituted for the 1/15M phosphate buffer, pH 7.4, used in the radioenzymatic assay.

Fig. 2. Salt inhibition of amniotic fluid DAP (O) and maternal serum DAO (X). The increasing salt concentrations were prepared in the 1/15M phosphate buffer, pH 7.4, used in the radioenzymatic assay.

Fig. 3. Sodium dodecyl sulfate gel electrophoresis on a 10% polyacrylamide gel of purified maternal serum DAO (lane 5, ←) and amniotic fluid DAO (lane 4, →) eluted with 1M NaCl from the Cadaverine-Sepharose affinity column. These were compared to maternal serum DAO (lane 6) and amniotic fluid DAO (lane 1) purified by DAE-Sepharose affinity chromatography. Calibration curves were constructed from the protein markers in lane 2 (LMW standards, PHARMACIA) and lanes 3 and 7 (SDS-PAGE LMW standards, BIORAD).

Fig. 4. Sodium dodecyl sulfate gel electrophoresis on a 12.5% polyacrylamide gel of purified maternal serum DAO (lane 3, ←) eluted with heparin from the Cadaverine-Sepharose affinity column. Amniotic fluid DAO was purified by heparin (lane 2, →) and 1M NaCl (lane 4) elution from the Cadaverine-Sepharose affinity column. Calibration curves were constructed from the protein markers in lanes 1 and 5 (LMW standards, PHARMACIA).

Fig. 5. Continuous sodium dodecyl sulfate gel electrophoresis on a 7.5% continuous polyacrylamide gel of purified maternal serum DAO eluted with heparin (lane 2) and 1M NaCl (lane 5), with purified amniotic fluid DAO eluted with heparin (lane 3) and 1M NaCl (lane 6). The proteins were eluted from the Cadaverine-Sepharose affinity column and further purified by HPLC gel permeation chromatography. Calibration curves were constructed from the protein markers in lanes 1 and 7 (LMW standards, PHARMACIA) and lane 4

(Prestained SDS-PAGE standards, BIORAD).

Fig. 6. Gradient gel electrophoresis performed on a PAA 4/30 polyacrylamide gel on purified maternal serum DAO eluted with heparin (lane 3) and 1M NaCl (lane 6), and purified amniotic fluid DAO eluted with heparin (lanes 4 and 7) and 1M NaCl (lanes 2 and 8). The proteins were eluted from the Cadaverine-Sepharose affinity column; calibration curves were constructed from the protein markers in lanes 1 and 5 (HMW standards, PHARMACIA).

Fig. 7. Agarose IEF performed in pH 3-10 Pharmalyte. Samples of maternal serum DAO purified by heparin (lane 4) and 1M NaCl (lane 7), and amniotic fluid DAO purified by heparin (lane 6) and 1M NaCl [(lane 3) faint bands], were eluted from the Cadaverine-Sepharose affinity column and put through the HPLC gel permeation column. The protein pattern in lane 5 is that of maternal serum DAO purified by DAH-Sepharose affinity chromatography. The calibration curves were constructed from the broad pH range [(pH range 3-10), lanes 1 and 8] and low pH range [(pH range 2.5-6.5), lanes 2 and 9] standard proteins (PHARMACIA).

Fig. 8. Agarose IEF performed in pH 4-9 Servalyte. Samples of maternal serum DAO eluted with 1M NaCl (lane 4) and amniotic fluid DAO eluted with 1M NaCl (lane 3) from the Cadaverine-Sepharose affinity column and put through the HPLC gel permeation column. These patterns were compared with maternal serum DAO (lane 5) and amniotic fluid DAO (lane 6) purified by DAH-Sepharose and Sephadex G-200 chromatography. The calibration curves were constructed from the broad pH range [(pH range 3-10) lanes 1 and 8] and low pH range [(pH range 2.5-6.5) lanes 2 and 7] standard proteins (PHARMACIA).

Fig. 9. Agarose gel electrophoresis performed on Cadaverine-Sepharose purified maternal serum DAO (heparin eluted, lane 4) and amniotic fluid DAO eluted with heparin (lane 5) and 1M NaCl (lane 3). The purified protein patterns were compared to those of maternal serum (lanes 1 and 7) and

amniotic fluid (lanes 2 and 5).

Fig. 10. Activity studies performed on amniotic fluid DAO and maternal serum DAO. Both species of DAO were purified by heparin elution off the Cadaverine-Sepharose affinity column and electrophoresed on a 1% agarose gel. Enzyme activity (dpm) was determined from sectioned gels by radioenzymatic analysis.

Fig. 11. Immunofixation and protein electrophoresis on agarose gels. Immunofixation patterns of amniotic fluid (lane 6) and maternal serum (lane 2) after incubation with polyclonal antisera. Polyclonal antisera immunoabsorbed with maternal serum and purified maternal serum DAO in a ratio of 50:1:0.3 removed all activity towards maternal serum (lane 4). In direct comparison, purified samples of DAO eluted with heparin off the Cadaverine-Sepharose column from amniotic fluid (lane 7, ◀) and maternal serum (lane 1, ▶) were run on the same gel and stained for proteins. Maternal serum (lane 3) and amniotic fluid (lane 5) were also protein stained as markers.

Fig. 12. Approximately 30ug of protein was applied to the Beckman gel and electrophoresed prior to application of the antihuman amniotic fluid DAO antisera. Antihuman amniotic fluid DAO antisera was then applied to cellulose acetate strips which were then placed onto the gel over the area of protein electrophoresis. The samples were; maternal serum (1), serum DAO (2), amniotic fluid DAO (3) and native amniotic fluid (4).

Fig. 13. Immunoprecipitation of amniotic fluid and maternal serum by incubation of 0.5ml of both fluids with the different volumes of the monoclonal antibody and polyclonal antisera. The immunoprecipitate was removed by centrifugation and the remaining enzyme activity was determined by radioenzymatic analysis.

Fig. 14. Immunofixation performed on three patient samples using the immunoabsorbed antiserum specific for amniotic

fluid diamine oxidase. Samples from two normal patients are shown in lanes 1 and 2 and a sample from a patient suspected clinically of having ruptured the amniotic membrane is shown in lane 3.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-

1. A method of preparing a purified form of serum diamine oxidase (S-DAO) or amniotic fluid diamine oxidase (AF-DAO) which includes the steps of:

(i) passing a preparation of S-DAO and AF-DAO through a first column or medium capable of binding glycoproteins or proteins being associated therewith carbohydrate groups;

(ii) eluting the preparation of AF-DAO and S-DAO from the column;

(iii) passing the preparation of S-DAO and AF-DAO through a second column or medium having binder or ligand which binds to active sites of AF-DAO and S-DAO; and

(iv) eluting the AF-DAO and S-DAO from the second column.

2. A method as claimed in claim 1 wherein the first column or medium comprises Sepharose having attached thereto lectins.

3. A method as claimed in claim 2 wherein the lectins comprise concavalin A or wheat germ agglutinin.

4. A method as claimed in claim 2 wherein the first column or medium comprises lentil lectin sepharose 4B or wheat germ lectin Sepharose 4B.

5. A method as claimed in any preceding claims wherein elutants for use in step (ii) include carbohydrate molecules or sugars or sugar derivatives.

6. A method as claimed in claim 5 wherein the elutants are selected from alpha-D-methyl mannoside, alpha-D-methyl glucoside, mannose or glucose.

7. A method as claimed in any preceding claim wherein the second column or medium includes an inert support having attached thereto a ligand which has a terminal free amino group.

8. A method as claimed in claim 7 wherein suitable ligands are those bearing the formula $\text{NH}_2-(\text{CH}_2)_n-\text{NH}_2$ wherein

n is 1-8.

9. A method as claimed in any preceding claim wherein elutants utilized in step (iv) include salts of concentrations up to IM and heparin.

10. A purified form of serum DAO having the following physical properties:

(i) a molecular weight of approximately 75,000 performed by SDS-PAGE with gels of different acrylamide concentrations;

(ii) a native molecular weight analysis as determined by gradient-PAGE or gel filtration chromatography revealed a number of species with molecular weights of 120,000; 160,000 and 480,000 daltons.

(iii) isoelectric focusing studies revealed a pattern characteristic of a glycoprotein and with substantial bands with isoelectric points greater than 5.

(iv) analysis of the purified enzyme by electrophoresis on agarose gels and immunofixation with polyclonal antisera revealed multiple bands of activity different to those bands corresponding to amniotic fluid DAO; and

(v) immunoabsorption of the polyclonal antiserum raised to amniotic fluid DAO with maternal serum and purified material serum DAO removed all reactivity to the maternal serum proteins when tested by immunofixation.

11. A purified form of amniotic fluid DAO having the following physical properties:

(i) a subunit molecular weight of approximately 79,000 determined by SDS-PAGE with gels of different acrylamide concentrations;

(ii) a native molecular weight determined by gradient-PAGE or gel filtration chromatography revealed a number of species of molecular weight 120,000; 160,000 and 480,000 daltons.

(iii) isoelectric focusing studies revealed a

pattern characteristic of glycoproteins with the isoelectric points of the bands being generally below 5.0.

(iv) analysis of the purified enzyme by electrophoresis on agarose gels and immunofixation with polyclonal antisera revealed multiple bands of activity different to these bands corresponding to serum DAO; and

(v) immunoadsorption of the polyclonal antiserum raised to amniotic fluid DAO with maternal serum and purified maternal serum DAO removed all reactivity to the maternal serum proteins when tested by immunofixation but retained activity to amniotic fluid DAO.

12. An assay for the diagnosis of rupture of amniotic membranes in pregnant mammals or leakage of amniotic fluid including the step of detecting the presence of amniotic fluid DAO in vaginal fluid and distinguishing same from serum DAO.

13. An assay as claimed in claim 12 including the step of developing a polyclonal or monoclonal antibody to S-DAO or AF-DAO or both.

14. An assay as claimed in claim 13 wherein polyclonal antiserum is developed to amniotic fluid DAO which is subsequently immunoadsorbed with maternal serum and purified serum DAO before immunofixation with vaginal fluid.

15. An assay for the detection of amniotic fluid DAO in a body fluid including the step of testing for the presence of amniotic fluid DAO in said body fluid by distinguishing same from serum DAO.

16. An assay for detection of diagnosis of rupture of the amniotic membrane in pregnant mammals which includes the steps of:-

- (i) obtaining a sample of vaginal fluid from a pregnant female;
- (ii) reacting the sample with antibody derived from amniotic fluid DAO; and
- (iii) detection of reactivity with a signal

amplification

1/20

TABLE 2. Purification of amniotic fluid diamine oxidase by DAH-Sepharose affinity chromatography

Purification	Total Volume (ml)	Total Protein (mg)	Total Activity (dpm)	Specific Activity (dpm/mg)	Purification (Fold)	Yield (%)
Amniotic Fluid	90	414	285×10^4	6884	1	100
Dialysis	100	310	263×10^4	8484	1.4	92.4
Affinity Stage	50	11.4	823650	72250	10.5	28.9
Dialysis	55	11.2	820800	73286	10.6	28.8

2/20

TABLE 3. Purification of maternal serum diamine oxidase by DAH- Sepharase affinity chromatography.

Purification	Total Volume (ml)	Total Protein (mg)	Total Activity (dpm)	Specific Activity (dpm/mg)	Purification (Fold)	Yield (%)
Amniotic fluid	100	7000	45×10^5	642	1	100
Dialysis	125	5900	39×10^5	661	1.03	86.7
Affinity Stage	40	26.8	684000	25522	39.7	15.2
Dialysis	45	24.4	489500	20471	31.8	11.1

3/20

TABLE 4. Purification of amniotic fluid diamine oxidase by Con A-Sepharase and cadaverine-Sepharase affinity chromatography

Purification	Total Volume (ml)	Total Protein (mg)	Total Activity (dpm)	Specific Activity (dpm/mg)	Purification (Fold)	Yield (%)
Amniotic fluid	200	900	592×10^4	6578	1	100
Post Con A-Sepharase	395	123	180×10^4	14615	2.22	30.4
Affinity Stage	50	3.1	63×10^4	203226	30.9	10.64

4/20

TABLE 5. Purification of maternal serum diamine oxidase by Con A-Sepharase and cadaverine-Sepharase affinity chromatography.

Purification	Total Volume (ml)	Total Protein (mg)	Total Activity (dpm)	Specific Activity (dpm/mg)	Purification (Fold)	Yield (%)
Amniotic Fluid	100	7000	290×10^4	415	1	100
Post Con A-Sepharase	350	490	55×10^4	1122	2.7	18.96
Affinity Stage	45	14.4	324800	22555	54.5	11.2

5/20

TABLE 6. Purification of amniotic fluid diamine oxidase by Con A-Sepharase and cadaverine-Sepharase affinity chromatography.

Purification	Total Volume (ml)	Total Protein (mg)	Total Activity (dpm)	Specific Activity (dpm/mg)	Purification (Fold)	Yield (%)
Amniotic Fluid	160	720	404×10^4	5611	1	100
Post Con A-Sepharase	250	106.8	165×10^4	15409	2.74	40.76
Affinity Stage	42	3.36	84×10^4	25×10^4	44.5	20.8

6/20

TABLE 7. Purification of maternal serum diamine oxidase by Con A-Sepharase and cadaverine-Sepharase affinity chromatography

Purification	Total Volume (ml)	Total Protein (mg)	Total Activity (dpm)	Specific Activity (dpm/mg)	Purification (Fold)	Yield (%)
Amniotic Fluid	100	7000	290×10^4	4141	1	100
Post Con A-Sepharase	310	570	806×10^3	1409	3.40	27.86
Affinity Stage	30	13.6	405×10^3	29830	72.0	14.0

7/20




FIG. 1

8/20




FIG. 2

9/20




FIG. 3

SUBSTITUTE SHEET




FIG. 4

11/20




FIG. 5

12/20




FIG. 6

13/20




FIG. 7

SUBSTITUTE SHEET

14/20




FIG. 8

15/20




FIG. 9

SUBSTITUTE SHEET

16/20




FIG. 10

17/20




FIG. 11

18/20




FIG. 12

19/20




FIG. 13

20/20




FIG. 14

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) 6

According to International Patent Classification (IPC) or to both National Classification and IPC

Int. Cl.⁵ C12N 9/06, C12Q 1/26

II. FIELDS SEARCHED

Minimum Documentation Searched 7

Classification System	Classification Symbols
IPC	Derwent databases: WPI, WPIL, USPA: keywords Diamine Oxidase, Diamino Oxhydrase, Histaminase, Amine Oxidase

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched 8

AU : IPC as above

CHEM ABS using keywords: Diamine Oxidase, Diamino Oxhydrase

III. DOCUMENTS CONSIDERED TO BE RELEVANT 9

Category*	Citation of Document, with indication, where appropriate, of the relevant passages 12	Relevant to Claim No 13
A	FR,A, 2101095 (INSTITUT MERIEUX) 31 March 1972 (31.03.72)	1-9
A	Chemical Abstracts, Volume 107, no. 23, issued 1987, December 7 (Columbus, Ohio, U.S.A.) W.J. Choi and D.H. Bae, 'study on diamine oxidase activity in human amniotic and chorionic tissues' see page 249, column 1, abstract no 213869e, Chungang Uidaechi, 1987, 12(2) 273-80 (Korean).	12
A	Chemical Abstracts, volume 108, no. 1, issued 1988 January 4 (Columbus, Ohio, U.S.A.) D.H. Kim and D.H. Bae, 'Biochemical study for characteristics of diamine oxidase in human early and term placenta' see page 371 column 1, abstract no. 3810y, Chungang Uidaechi, 1987, 12(1), k75-85 (Korean).	12

(continued)

* Special categories of cited documents: 10

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date, but later than the priority date claimed

"T"

Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&"

document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the
International Search
20 June 1990 (20.06.90)Date of Mailing of this International
Search Report

27 June 1990

International Searching Authority

Signature of Authorized Officer

Australian Patent Office

GRANT MCNEICE

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	Chemical Abstracts, volume 108, no. 9, issued 1988 February 29 (Columbus Ohio, U.S.A.), O. Suzuki and T. Matsumoto, 'Purification and properties of diamine oxidase from human kidney', see page 289, column 1, abstract no. 71072j, Biog. Amines, 1987, 4(3), 237-45 (Eng).	1-9
---	--	-----

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim numbers ..., because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers ..., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers ..., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4 (a):

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 2

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON
INTERNATIONAL APPLICATION NO. PCT/AU 90/00085

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document
Cited in Search
Report

Patent Family Members

FR 2101095

END OF ANNEX

